Advertisement

Rheumatology International

, Volume 38, Issue 6, pp 1083–1088 | Cite as

Pseudogout among Patients Fulfilling a Billing Code Algorithm for Calcium Pyrophosphate Deposition Disease

  • Sara K. Tedeschi
  • Daniel H. Solomon
  • Katherine P. Liao
Observational Research
  • 62 Downloads

Abstract

To test the performance of a billing claims-based calcium pyrophosphate deposition disease (CPPD) algorithm for identifying pseudogout. We applied a published CPPD algorithm at an academic institution and randomly selected 100 patients for electronic medical record review for 3 phenotypes: (1) definite/probable CPPD, (2) definite/probable pseudogout; (3) definite pseudogout. Clinical data were recorded and positive predictive value (PPV) (95% CI) for each phenotype was calculated. We then modified the published algorithm to require ≥ 1 of 4 relevant terms (“pseudogout”, “calcium pyrophosphate crystals”, “CPPD”, or “chondrocalcinosis”) through automated text searching in clinical notes, and re-calculated PPVs. To estimate the percentage of pseudogout patients not identified by the published algorithm, we reviewed a random sample of 50 patients with ≥ 1 of 4 relevant terms in clinical notes who did not fulfill the published algorithm. Among patients fulfilling the published algorithm, 68% had ≥ 1 of 3 phenotypes. The published algorithm had PPV 24.0% (95% CI 19.3–28.7%) for definite/probable pseudogout and 18.0% (95% CI 14.5–21.5%) for definite pseudogout. Requiring ≥ 1 of 4 relevant terms in clinical notes increased PPV to 33.3% (95% CI 26.8–39.8%) for definite/probable pseudogout and 24.6% (95% CI 19.8–29.4%) for definite pseudogout. Among patients not fulfilling the published algorithm, 16.0% had definite/probable pseudogout and 6.0% had definite pseudogout. A billing code-based CPPD algorithm had low PPV for identifying pseudogout. Adding text searching modestly enhanced the PPV, though it remained low. These findings highlight the need for improved approaches to identify pseudogout to facilitate epidemiologic studies.

Keywords

Pseudogout Calcium pyrophosphate CPPD Algorithm 

Notes

Author contributions

SKT collected and analyzed electronic medical record data, interpreted results, and was a major contributor to the manuscript. DHS and KPL contributed to study design, interpretation of results, and manuscript preparation. All authors read and approved the final manuscript.

Funding

This work was supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases at the National Institutes of Health [L30 AR070514, K24 AR055989, and P30 AR072577]. The funding source had no rule in study design or collection, analysis and interpretation of the data or manuscript preparation.

Compliance with ethical standards

Conflict of interest

Dr. Tedeschi, Dr. Solomon, and Dr. Liao declare that they have no conflict of interest.

Ethical approval

For this type of study formal consent is not required.

References

  1. 1.
    McCarty DJ (1977) Calcium pyrophosphate dihydrate crystal deposition disease: Nomenclature and diagnostic criteria. Ann Intern Med 87:241–242CrossRefPubMedGoogle Scholar
  2. 2.
    Rosenthal AK, Ryan LM (2016) Calcium pyrophosphate deposition disease. N Engl J Med 374:2575–2584CrossRefPubMedGoogle Scholar
  3. 3.
    Ryan L, McCarty D (1985) Calcium pyrophosphate crystal deposition disease; pseudogout; articular chondrocalcinosis. In: McCarty D (ed) Arthritis and allied conditions, 10th edn. Lea & Febiger, Philadelphia, pp 1515–1546Google Scholar
  4. 4.
    Zhang W, Doherty M, Bardin T, Barskova V, Guerne PA, Jansen TL et al (2011) European league against rheumatism recommendations for calcium pyrophosphate deposition. Part i: Terminology and diagnosis. Ann Rheum Dis 70:563–570CrossRefPubMedGoogle Scholar
  5. 5.
    Rho YH, Zhu Y, Zhang Y, Reginato AM, Choi HK (2012) Risk factors for pseudogout in the general population. Rheumatology 51:2070–2074CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Roddy E, Muller S, Paskins Z, Hider SL, Blagojevic-Bucknall M, Mallen CD (2017) Incident acute pseudogout and prior bisphosphonate use: matched case-control study in the uk-clinical practice research datalink. Medicine (Baltimore) 96:e6177CrossRefGoogle Scholar
  7. 7.
    Bartels CM, Singh JA, Parperis K, Huber K, Rosenthal AK (2015) Validation of administrative codes for calcium pyrophosphate deposition: a veterans administration study. J Clin Rheumatol 21:189–192CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Tedeschi SK, Solomon DH, Liao KP (2017) Pseudogout among patients fulfilling a billing code algorithm for calcium pyrophosphate deposition disease (cppd) [abstract]. Arthritis Rheum 69Google Scholar
  9. 9.
    Neogi T, Jansen TL, Dalbeth N, Fransen J, Schumacher HR, Berendsen D et al (2015) 2015 gout classification criteria: an american college of rheumatology/european league against rheumatism collaborative initiative. Arthritis Rheumatol 67:2557–2568CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO et al (2010) rheumatoid arthritis classification criteria: an american college of rheumatology/european league against rheumatism collaborative initiative. Arthritis Rheum 2010;62:2569–2581CrossRefPubMedGoogle Scholar
  11. 11.
    Liao KP, Cai T, Savova GK, Murphy SN, Karlson EW, Ananthakrishnan AN et al (2015) Development of phenotype algorithms using electronic medical records and incorporating natural language processing. BMJ 350:h1885CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Harrold LR, Yood RA, Mikuls TR, Andrade SE, Davis J, Fuller J et al (2006) Sex differences in gout epidemiology: evaluation and treatment. Ann Rheum Dis 65:1368–1372CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Division of Rheumatology, Immunology and AllergyBrigham and Women’s HospitalBostonUSA

Personalised recommendations